期刊文献+

79例奥沙利铂相关不良反应分析 被引量:5

Analysis of 79 Cases of Oxaliplatin Adverse Reactions
原文传递
导出
摘要 目的探讨奥沙利铂(L-OHP)不良反应的发生特点,为临床合理用药提供参考。方法收集我院2005~2016年上报的关于L-OHP不良反应报告并进行相关文献复习。结果共收集到L-OHP相关不良反应报告79例,不良反应发生时间主要在3~120 min之间,中位周期为第6周期,中位累积剂量为557.6 mg/m^2,不良反应大都以过敏反应和神经毒性为主,Ⅲ级以上的不良反应报告有7例。结论 L-OHP的不良反应呈现剂量累积性,治疗前适当的预处理措施以及用药宣教可以降低奥沙利铂不良反应的发生率。 OBJECTIVE To discuss the characteristics of occurrence of ADRs induced by oxaliplatin( L-OHP),and to provide information for rational clinical use of the drug. METHODS ADR reports of L-OHP were collected from 2005- 2016 and related literatures were reviewed. RESULTS Among the 79 ADR reports collected,ADRs mainly occurred in 3-120 min after injection. The median chemotherapy period was the sixth cycle with a median cumulative dose 557.6 mg / m^2. Allergy and neurotoxicity were the major performances. 7 cases of severe adverse reaction were reported. CONCLUSION The ADRs of L-OHP appeared to correlate with the cumulative dose. Proper preparative regimens before treatment and medication education may reduce the incidence of ADR caused by LOHP.
作者 陈曙东 周永刚 吴冬妮 CHEN Shudong ZHOU Yonggang WU Dongni(Department of Pharmacy, the Affiliated Bayi Hospital of Nanjing University of Chinese Medicine, nanjing ,jiangsu 21002, China)
出处 《今日药学》 CAS 2017年第1期45-47,共3页 Pharmacy Today
关键词 奥沙利铂 不良反应 累积剂量 oxaliplatin adverse reaction cumulative dose
  • 相关文献

参考文献11

二级参考文献119

  • 1濮雪芹.药品不良反应与合理用药的几点思考[J].中国食品药品监管,2008,0(12):33-34. 被引量:2
  • 2马飞,袁芃,徐泉,徐兵河.奥沙利铂所致急性神经毒性的临床分析及其治疗(附1例报告)[J].临床肿瘤学杂志,2005,10(5):533-535. 被引量:52
  • 3Miseet JL.Oxaliplatin in practice[J].Br J Cancer,1998,77(Suppl 4):4-7.
  • 4Lévi F,Zidani R,Vannetzel JM,et al.Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin,fluorouracil,and folinic acid in patients with colorectal cancer metastases:a randomized multi-institutional trial[J].J Natl Cancer Inst,1994,86(21):1608-1617.
  • 5André T,Boni C,Navarro M,et al.Improved overall survival with oxaliplatin,fluorouracil,and leucovorin as adjuvant treatmerit in stage Ⅱ or Ⅲ colon cancer in the MOSAIC trial[J].J Clin Oncol,2009,27(19):3109-3116.
  • 6Mathe G,Kidani Y,Noji M,et al.Antitumor activity of L-OHP in mice[J].Cancer Lett,1985,27(2):135-143.
  • 7Rixe O,Ortuzar W,Alvarez M,et al.Oxaliplatin,tetraplat-in,cisplatin and carboplatin:spectrum of activity in drugresistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel[J].Biochem Pharmanol,1996,52(12):1855-1865.
  • 8Figer A,Homerin M,Seymour M,et al.Leucovorin and 5-fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J].J Clin Oncol,2000,18(16):2938-2947.
  • 9Wilson RH,Lehky T,Thomas RR,et al.Acute oxaliplatin induced peripheral nerve hyperexcitability[J].J Clin Oncol,2002,20(7):1767-1774.
  • 10Adelsberger H,Quasthoff S,Grosskreutz J,et al.The chemotherapeutic oxaliplatin alters voltage gated Na(+) channel kinetics on rat sensory neurons[J].Eur J Pharmacol,2000,406(1):25-32.

共引文献130

同被引文献39

引证文献5

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部